Physician profile
Thomas L Voitier
NPI 1598906570
$713.15
in general payments reported to CMS, 2019-2025
20 companies · $42.70 in 2025
The $42.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $69.20 · 2021: $13.34 · 2022: $30.26 · 2023: $13.19 · 2024: $54.04 · 2025: $42.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $106.42 | 2019-2020 | |
| Amgen INC. | $75.86 | 2019-2020 | |
| Glaxosmithkline, LLC. | $66.34 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $47.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.11 | 2019-2020 | |
| Shire North American Group INC | $43.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.98 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.95 | 2019 | |
| Abbott Laboratories | $34.00 | 2023-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.81 | 2019 | |
| Amarin Pharma, INC. | $28.99 | 2019 | |
| Allergan, INC. | $27.52 | 2019-2020 | |
| Novo Nordisk INC | $24.89 | 2019-2024 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $20.83 | 2019 | |
| Abbvie INC. | $18.55 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.42 | 2020 | |
| Merck Sharp & Dohme LLC | $13.65 | 2019 | |
| Lilly USA, LLC | $11.71 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.21 | 2025 | Voquezna |
| Pfizer INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Voitier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.